About Dr Waleed Mohammed

BA (Cantab), MSc (Oxon), MBBChir (Cantab), MRCP (Lond), FRCR

Specialities:

Clinical oncology
Lung oncology
Neuro-oncology
Cancer services

Dr Waleed Mohammed is a consultant clinical oncologist specialising in the treatment of thoracic and central nervous system cancers. He combines advanced radiotherapy techniques with systemic therapies to deliver personalised cancer care, with a focus on achieving the best possible outcomes while maintaining quality of life.

Primary and secondary thoracic cancers (such as NSCLC, SCLC, LCNET, mesothelioma and thymic cancers)

Primary and secondary CNS (brain and spine) cancers (LGG, HGG, meningioma, ependymoma, medulloblastoma, pituitary tumours, pineal tumours, and intra-cranial germ cell tumours)

  • Radiotherapy
  • Cancer Care
  • Stereotactic Ablative Radiotherapy (SABR)
  • Linac-based Stereo-tactic Ablative Radiotherapy (SABR)
  • MR-Linac (MRL) SABR
  • Chemotherapy
  • Gamma Knife Radiosurgery
  • Biological Therapy
  • Image Guided Radiotherapy (IGRT) 
  • Immunotherapy
  • Immunotherapy/Check-Point Inhibitors (IO/CPI)
  • Intensity Modulated Radiotherapy (IMRT)
  • Neoadjuvant
  • Oral Tyrosine Kinase Inhibitors (TKIs)
  • Stereotactic Radiosurgery (SRS)
  • Linac-based Stereotactic Radiosurgery (SRS)
  • Gamma Knife based SRS (including frame-fitting and Optune Tumour Treating Fields (TTF).
  • Targeted Therapy
  • Cytotoxic Systemic Anti-Cancer Therapy (SACT)
  • Volume Modulated Arc Therapy (VMAT)
  • Charing Cross Hospital, London
  • Imperial College Healthcare NHS Trust, London
  • GenesisCare London Cromwell Hospital
  • LOC at Harley Street Clinics, London

Dr Waleed Mohammed is a consultant clinical oncologist with a background in genetics, bio-sciences and clinical medicine.

Dr Mohammed initially trained as a bio-scientist, specialising in genetics at the University of Cambridge before completing an MSc in Biology at the University of Oxford. He conducted genetics-related research, focusing on lysosomal storage disorders and prion diseases with the aim of developing drug therapy.

He worked in the pharmaceutical industry at the start of his career, firstly at Oxford Science Park and later at the MRC Prion Unit at Queen Square, University College London.

Dr Mohammed later retrained as a medic through the Cambridge Graduate Course in Medicine, specialising in clinical oncology. He underwent specialist registrar training at various prestigious institutions, including Imperial College NHS Trust, The Royal Marsden Hospital, and The Royal Sussex County Hospital. In 2020, he became a consultant clinical oncologist at Charing Cross Hospital where he established the Stereotactic Ablative Radiotherapy (SABR) service.

Dr Mohammed speaks English and Arabic.

Dr Mohammed is a member of The Royal College of Physicians (London) and a Fellow of The Royal College of Radiologists. He received the New Fellows Speaker Award.

Dr Mohammed is sub-investigator in various clinical trials. As an oncology trainee, he investigated the short-term toxicity of brachytherapy in prostate cancer patients with inflammatory bowel disease and was awarded first prize for best presentation at an international conference. At the start of his career, as a geneticist, Dr Mohammed researched the role of newly discovered genes in the development of early mouse embryos.

  • PKorolewicz JA, Scheiner B, Fulgenzi CAM, D’Alessio A, Cortellini A, Pascual C, Mehan A, Partridge S, Gujral DM, Mohammed W, Mohammed O, Grzesiak A, Booker L, Cleator S, Pokrovska T, Saleem W, Rackie J, Needham Y, Krell J, McNeish I, Tookman L, Park WE, Asif M, Evans JS, Pinato DJ. The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden. Chemotherapy. 2024 Apr 27:1-7. doi: 10.1159/000539109. Epub ahead of print. PMID: 38679017
  • Hamish Sinclair, Kerlann Le Calvez, Jiarong Chen, Lillie Pakzad-Shahabi, Luke Dixon, Waleed Mohammed, Waqar Saleem, Matthew Williams, Estimating population-based incidence of brain metastases – a comprehensive incident cohort study, Neuro-Oncology, Volume 23, Issue Supplement_4, October 2021, Page iv21, https://doi.org/10.1093/neuonc/noab195.053 
  • Seema Dadhania, Lillie Pakzad-Shahabi, Kerlann Le Calvez, Waqar Saleem, James Wang, Waleed Mohammed, Sanjay Mistry, Matthew Williams, BrainWear: Longitudinal, objective assessment of physical activity in 42 High Grade Glioma (HGG) patients, Neuro-Oncology, Volume 23, Issue Supplement_4, October 2021, Page iv3, https://doi.org/10.1093/neuonc/noab195.006 

Holistic Support

As part of a holistic approach to cancer care, Dr Mohammed works alongside trusted health coaching professionals to support patients throughout treatment and recovery.

Stephanie vom Hagen is a certified health coach who provides personalised support focused on wellbeing, resilience and helping patients adapt to life during and after cancer treatment. Her coaching complements medical care by supporting physical and emotional wellbeing through practical, realistic lifestyle changes.

www.stephanievomhagen.com